English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
CML Publications 2017
| Clinical Publications | Scientific Publications |
| December 2017 | |
| Treatment-free remission in CML: who, how, and why? (Mahon FX. Hematology Am Soc Hematol Educ Program, December 2017) |
Exosomes derived from imatinib-resistant chronic myeloid leukemia cells mediate a horizontal transfer of drug-resistant trait by delivering miR-365 (Min QH et al. Exp Cell Res, December 2017) (epub ahead of print) |
| Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy (Barber MC et al. Hematology Am Soc Hematol Educ Program, December 2017) |
Ecotopic viral integration site 1 (EVL1) transcriptionally targets talin 1 (TLN1) and upregulates its expression in chronic myeloid leukemia (Halder A et al. Leuk Lymphoma, December 2017) (epub ahead of print) |
| Novel approaches to therapy in CML (Bhatia R et al. Hematology Am Soc Hematol Educ Program, December 2017) |
C1206, a novel curcumin derivate, potently inhibits Hsp90 and human chronic myeloid leukemia cells in vitro (Fan YL et al. Acta Pharmacol, December 2017) (epub ahead of print) |
| Front-line treatment options for chronic-phase chronic myeloid leukemia (Shah NP et al. J Clin Oncol, December 2017) (epub ahead of print) |
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib (Giallongo C et al. J Cell Mol Med, December 2017) (epub ahead of print) |
| Mechanisms of resistance to targeted therapies in chronic myeloid leukemia (Lussana F et al. Handb Exp Pharmacol, December 2017) (epub ahead of print) |
Controversies regarding use of myeloid growth factors in leukemia (Poston JN et al. J Natl Compr Canc Netw, December 2017) |
| Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapharesis appropriate? A case report and review of the literature (Staley EM et al. Transfusion, December 2017) (epub ahead of print) |
|
|
Atypcial chronic myeloid leukemia: a rare entity with management challenges (Dhakal P et al. Future Oncol, December 2017)(epub ahead of print) |
|
|
Successful ovarian stimulation for fertility preservation in a patient with chronic myeloid leukemia: switch from nilotinib to interferon-alpha |
|
| November 2017 | |
| Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BEFORE trial (Cortes JE et al. J Clin Oncol, November 2017) (epub ahead of print) |
Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and authophagy inhibition (Mitchell R et al. J Natl. Cancer Inst, November 2017) (epub ahead of print) |
| Bosutinib more effective than imatinib in CML (Gourd E. Lancet Oncol, November 2017) (epub ahead of print) |
Off-target effect of imatinib and nilotinib on human vitamin D3 metabolism |
| Clinical efficacy and safety of first-line dasatinib therapy and the relevance of velocity of BCR-ABL1 transcript decline for achievement of molecular chronic-phase chronic myeloid leukemia: Report from the Juntendo Yamanashi Cooperative Study Group (Takaku T et al. Oncology, November 2017) (epub ahead of print) |
|
| Immature CML cells implement a BMP autocrine loop to escape TKI treatment (Grockowiak E et al. Blood, November 2017) |
|
| Prognostic relevance of CCAs/Ph- CML settled (Hehlmann R et al. Blood, November 2017) |
|
|
Off-target effect of imatinib and nilotinib on human vitamin D3 metabolism |
|
| Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells (Lei H et al. Leuk Res, November 2017) (epub ahead of print) |
|
| Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in CML cells (Hirao T et al. Cancer Sci, November 2017) (epub ahead of print) |
|
| October 2017 | |
| Long-term patient-reported outcomes from an open-label safety and efficacy study on bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy (Kantarjian HM et al. Cancer, October 2017) (epub ahead of print) |
Transgenic expression of human cytokines in immunodeficient mice does not facilitate myeloid expansion of BCR-ABL1 transduces human cord blood cells (Askmyr M et al. PLoS One, October 2017) |
| How I manage relapse of chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy (Rea D et al. Br J Haematol, October 2017) (epub ahead of print) |
Micro RNA-7 inhibits cell proliferation of chronic myeloid leukemia and sensitizes it to imatinib in vitro (Jiang MJ et al. Biochem Biophys Res Comm, October 2017) (epub ahead of print) |
| Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting (Boddu P et al. Leuk Lymphoma, October 2017) (epub ahead of print) |
Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARy-dependent manner in leukemia cells (Yousefi B et al. Tumour Biol, October 2017) |
| Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias (Cortes JE et al. Clin Lymphoma Myeloma Leuk, October 2017) |
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors (Alhuraiji A et al. Am J Hematol, October 2017) (epub ahead of print) |
| Dasatinib cessation after deep molecular response exceeding 2 years, and NK cell transition during dasatinib consolidation (Kumagai T et al. Cancer Sci, October 2017) (epub ahead of print) |
Membrane perturbation through novel cell-penetrating peptides influences intracellular accumulation of imatinib mesylate in CML cells (Mukherjee D et al. Cell Biol Toxicol, October 2017) (epub ahead of print) |
|
Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients |
Absolute bioavailability of bosutinib in healthy subjects from an open-label randomized, 2-period crossover study |
| Pleural effusion and molecular response in dasatinib treated chronic myeloid leukemia patients in a real-life Italian multicenter series (Iurlo A et al. Ann Hematol, October 2017) (epub ahead of print) |
Synergistic antiproliferative activity of the RAD51 inhibitor IBR2 with inhibitors of receptor tyrosine kinases and microtubule protein (Ferguson PJ et al. J Pharmacol Exp Ther, October 2017) (epub ahead of print) |
|
First-line therapy for chronic phase CML: selecting the optimal BCR-ABL-1-targeted TKI |
|
|
Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved |
|
|
The efficacy of reduced-dose dasatinib as a subsequent therapy in patients with chronic myeloid leukemia in the chronic phase: The LD-CML study of the Kanto CML Study Group |
|
| September 2017 | |
| Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase myeloid leukemia: the JALSG-STIM213 study (Takahashi N et al. Int J Hematol, September 2017) (epub ahead of print) |
High BCR-ABL/Gusis levels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib (Vigneri P et al. Clin Cancer Res, September 2017) |
| Rapid reduction of BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukemia patients (Murai K et al. Eur J Haematol, September 2017) (epub ahead of print) |
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells (Kuntz EM et al. Nat Med, September 2017) (epub ahead of print) |
| Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic-phase patients with chronic myeloid leukemia and from healthy controls (de Cássia Viu Carrara R et al. Clin Tranl Oncol, Sept. 2017) (epub ahead of print) |
|
|
A method for next-generation sequencing of paired diagnostic and remission samples to detect mitochondrial DNA mutations associated with leukemia |
|
|
Diagnostic and prognostic cytogenetics of chronic myeloid leukemia: an update |
|
| August 2017 | |
| The safety of bosutinib for the treatment of chronic myeloid leukemia (Kong JH et al. Expert Opin Drug Saf, August 2017) (epub ahead of print) |
CT-721, a potent BCR-ABL inhibitor, exhibits excellent in vitro and in vivo efficacy in the treatment of chronic myeloid leukemia (Sun Y et al. J Cancer, August 2017) |
| Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia (Assi R et al. Clin Lymphoma Myeloma Leuk, August 2017) (epub ahead of print) |
A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line |
| Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML Study IV and impact of non-CML determinants (Hehlmann R et al. Leukemia, August 2017) (epub ahead of print) |
Dasatinib reversibly disrupts endothelial vascular integrity by increasing non-muscle myosin II contractility in a ROCK-dependent manner (Kreutzmann A et al. Clin Cancer Res, August 2017) (epub ahead of print) |
| Impact of imatinib on the fertility of male patients with chronic myelogenous leukaemia in the chronic phase (Chang X et al. Target Oncol, August 2017) (epub ahead of print) |
SHP1 is required for BCR-ABL1-induced hematologic neoplasia (Gu S et al. Leukemia, August 2017) (epub ahead of print) |
|
Vascular adverse events during long-term nilotinib therapy in patients with chronic myeloid leukemia |
Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia |
|
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance |
A virtual screening approach for the identification of high affinity small molecules targeting BCR-ABL1 inhibitors for the treatment of chronic myeloid leukemia (Sharda S et al. Curr Top Med Chem, August 2017) |
|
|
Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response |
|
|
NCG2D gene polyphormisms are associated with disease control of chronic myeloid leukemia by dasatinib |
|
Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors |
|
|
Role and mechanisms of decitabine combined in advanced chronic myeloid leukemia cells |
|
| July 2017 | |
| Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients (Jain P et al. Cancer, July 2017) (epub ahead of print) |
Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315l mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex (Chen M et al. Oncotarget, July 2017) |
| Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia (Legros L et al. Cancer, July 2017) (epub ahead of print) |
Association between proteomic profile and molecular response in chronic myeloid leukemic patients (Garrisi VM et al. Leuk Lymphoma, July 2017) (epub ahead of print) |
| Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: Long-term follow-up (Aghel N et al. Clin Lymphoma Myeloma Leuk, July 2017) (epub ahead of print) |
Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment (Chelysheva E et al. Leuk Lymphoma, July 2017) (epub ahead of print) |
|
How to report adherence to treatment as clinically relevant data-making – a case of CML and TKI |
New tool for monitoring molecular response in patients with chronic myeloid leukemia |
| Treatment-free rmission in patients with chronic myeloid leukemia (Rea D et al. Int J Hematol, July 2017) (epub ahead of print) |
Specific monoclonal antibody against BCR/ABL out-of-frame alternative proteins as diagnostic tool in chronic myelogenous leukemia patients |
|
Nilotinib dose-optimization in newly diagnosed chronic myeloid leukemia in chronic-phase: final results from ENESTxtnd |
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase CML patients
(Mologni L et al. Am J Hematol, July 2017) |
|
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial |
Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1
(Edlinger L et al. Br J Haematol, July 2017) |
|
Post-transplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukaemia |
PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase |
|
Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival |
Clinical and prognostic significance of e1a2 BCR-ABL transcript subtype in chronic myeloid leukemia |
|
Chronic myeloid leukemia: Global impact from a local laboratory |
Imatinib and nilotinib off-target effects on human NK cells, monocytes, and M2 macrophages |
| Chronic myeloid leukemia: room for improvement? (Baccarani M et al. Haematologica, July 2017) |
|
| June 2017 | |
| Analyses of treatment outcome according to age in patients with chronic myeloid leukemia receiving front-line imatinib therapy (Cojbasic I et al. Clin Lymphoma Myeloma Leuk, June 2017) |
ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure (Marum JE et al. Blood Advances, June 2017) |
| Incidence of second primary malignancies and related myeloid leukemia patients (Gugliotta G et al. Haematologica, June 2017) (epub ahead of print) |
Understanding cancer from the stem cells up |
|
Evaluation of a new flow cytometry based method for detection of BCR-ABL1 fusion protein in chronic myeloid leukemia |
|
|
SHC004-221A1, a novel tyrosine kinase, potently inhibits T315l mutant BCR-ABL in chronic myeloid leukemia |
|
|
A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type y in chronic myeloid leukemia patients |
|
|
|
Genomic profiling of chronic myelogenous leukemia: Basis and clinical approach |
| Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence (Ianniciello A et al. Oncotarget, June 2017) |
|
| May 2017 | |
|
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial |
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKI’s therapy |
|
Natural killer cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study |
Chronic myeloid leukemia: Immunobiology and novel immunotherapeutic approaches |
|
Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML |
E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in persons with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy |
|
Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome |
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic-myeloid leukemia |
| Maternal, fetal and neonatal imatinib levels with treatment of chronic myeloid leukemia in pregnancy (Burwick RM et al. Obstet Gynecol, May 2017) |
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib (Gullaksen SE et al. Haematologica, May 2017) (epub ahead of print) |
|
New drugs and allogeneic hematopoietic stem cell transplantation for haematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? |
Micro RNA’s that affect the Fanconi Anemia / BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations (Yap E et al. Leuk Res, May 2017) (epub ahead of print) |
|
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib |
A novel BCR-ABL1 fusion gene with genetic heterogeneity indicates a good prognosis in a chronic myeloid leukemia case (Zhou F et al. Mol Cytogenet, May 2017) |
|
Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios |
Deregulated expression of MiR-299-3p, miR-494-3p and miR 660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells (Salati S et al. Oncotarget, May 2017) (epub ahead of print) |
|
Running the marathon of chronic myeloid leukemia with no shoes (or without the right shoes) |
A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD) (Duan MH et al. Leuk Res, May 2017) (epub ahead of print) |
|
Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcript by imatinib therapy |
BiRC6 mediates imatinib resistance independently of Mcl-1 (Okumu DO et al. PloS One, May 2017) |
|
Clinical impact of pre-transplant use of multiple tyrosine kinase inhibitors on the outcome of allo-HSCT for CML |
Cancer progression by reprogrammed BCAA metabolism in myeloid leukemia (Hattori A et al. Nature, May 2017) |
|
CML in blast crisis: more common than we think? |
Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukemia (Zhang X et al. Br J Haematol, May 2017) (epub ahead of print) |
|
Treating the chronic-phase myeloid leukemia patient: which TKI, when to switch and when to stop? |
Role of NOX2 for leukemic expansion in a murine model of BCR-ABL1+ leukemia (Grauers Wiktorin H et al. Br J Hematol, May 2017) (epub ahead of print) |
|
Are chronic myeloid leukemia patients ready to stop long-term treatment? |
Baseline BCR-ABL1 transcript type of 13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy (Lee SE et al. Leuk Lymphoma, May 2017) (epub ahead of print) |
|
|
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization
(Luatti S et al. Oncotarget, May 2017) (epub ahead of print) |
| Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukaemia treated with nilotinib (Gullaksen SE. Haematologica, May 2017) (epub ahead of print) |
|
| April 2017 | |
| Understanding CML, 1 cell at a time (Radich J et al. Blood, April 2017) |
Decreased Calpain activity in chronic myeloid leukemia impairs apoptosis by increasing Xiap1 in differentiating granulocytes
(Huang W et al. Oncotarget, April 2017) (epub ahead of print) |
|
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315l mutation |
A novel AHI-1-BCR-ABL-DNM2 complex regulated leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated authophagy |
|
TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
|
Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment |
|
The role of early molecular response in the management of chronic phase CML |
BCR-ABL 1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia
(Vasconcelos AP et al. Genet Mol Res, April 2017) |
|
Treatment and molecular monitoring update in chronic myeloid leukemia management |
|
|
Impact of age on efficacy and tolerability of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis |
|
|
Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase myeloid leukemia patients |
|
| March 2017 | |
| Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia (Hoffmann VS et al. J Cancer Res Clin Oncol, March 2017) |
The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase CML patients
|
|
Imatinib discontinuation in chronic myeloid leukemia patients with undetectable BCR-ABL transcript level: |
Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells (Tsubaki M et al. Oncotarget, March 2017) (epub ahead of print) |
| A BCR-ABL1 cutoff of 1,5 % at 3 months, determined by the GeneExpert System, predicts an optimal response in patients with chronic myeloid leukemia (García-Gutiérrez V. et al. PLoS One, March 2017) |
Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous leukemia cell growth (Bellavia D et al. Theranostics, March 2017) |
| Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20 mg (Itamura H et al. Clin Lymphoma Myeloma Leuk, March 2017) (epub ahead of print) |
Stelletin B induces apoptosis in human chronic myeloid leukemia cells via targeting Pi3K and Stat 5
(Chen Y et al. Oncotarget, March 2017) (epub ahead of print) |
|
Predictive parameters for imatinib failure in patients with chronic myeloid leukemia (Lekovic D et al. Hematology, March 2017) |
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL 1 |
|
Imatinib changed everything |
Is there an immune suveillance against chronic myeloid leukemia? Possibly, but not much |
| Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors (Maiti A et al. Leuk Lymphoma, March 2017) |
With no interaction, knockdown of Apollon and MDR1 reverse the multidrug resistance of human chronic myelogenous leukemia K562/ADM cells |
| Can any patients with chronic myeloid leukemia outside of clinical trial have their tyrosine kinase inhibitors discontinued? (Mauro MJ. Curr Opin Hematol, March 2017) |
MPT0B002, a novel microtube inhibitor downregulates T315l mutant BCR-ABL and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells |
|
Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5 year final report |
Carfilzomib induces leukemia cell apoptosis via inhibiting ELK1/Ki AA1524 (ELK-1/CIP2A) and activating PP2A not related to proteasome inhibition |
|
Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib |
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia |
|
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry |
p53 modulates the effect of ribosomal S6 kinase 1 (S6K1) cisplatin toxicity in chronic myeloid leukemia cells |
|
Long-term outcomes of imatinib treatment for CML |
Combined inhibition of ß-catenin and BCR-ABL synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo (Zhou H et al. Leukemia, March 2017) (epub ahead of print) |
|
Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries |
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia |
|
Treatment and outcomes of 2904 CML patients from the EUTOS population-based registry |
Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukemia: findings from an international EQA Programme |
| Unleasing the Guardian: The targetable BCR-ABL/HAUSP/PML/PTEN Network in chronic myeloid leukemia (Morotti A et al. Curr Drug Targets, March 2017) |
|
The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase inhibitors conferred by the deletion polymorphism in chronic myeloid leukemia (Rauzan M et al. PLoS One, March 2017) |
|
|
|
Blockade of Y177 and and nuclear translocation of BCR-ABL inhibits proliferation and promotes apoptosis in chronic myeloid leukemia cells (Li Q et al. Int J Mol Sci, March 2017) |
| February 2017 | |
| Pleural effusion in Dasatinib-treated patients with chronic myeloid leukemia in chronic phase: Identification and management (Cortes J et al. Clin Lymphoma Myeloma Leuk, February 2017) |
Molecular techniques for the personalised management of patients with chronic myeloid leukemia (Alikian M et al. Biomol Detect Quantif, February 2017) |
| Chronic myeloid leukemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome (Sora F et al. Br J Haematol, February 2017) (epub ahead of print) |
Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression |
| Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia (Chen Z et al. Blood Cancer J, February 2017) (epub ahead of print) |
Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast crisis chronic myeloid leukemia (Maiti A et al. Leuk Lymphoma, February 2017) (epub ahead of print) |
| Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st subanalysis (Hochhaus A et al. J Cancer Res Clin Oncol, February 2017) (epub ahead of print) |
CobII1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia (Han SH et al. Leukemia, February 2017) (epub ahead of print) |
| Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom Study (Hochhaus A et al. Leukemia, February 2017) (epub ahead of print) |
Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors (Asano M et al. Int J Hematol, February 2017) (epub ahead of print) |
| Stopping second-generation TKI's in CML (Laneuville P et al. Blood, February 2017) |
Differential signaling networks of BCR-ABL p210 and p190 kinases in leukemia cells defined by functional proteomics (Reckel et al. Leukemia, February 2017) (epub ahead of print) |
|
Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia? |
Differentiation status of primary chronic myeloid leukemia cells affect sensitivity to BCR-ABL1 inhibitors (Pietarinen PO et al. Oncotarget, February 2017) (epub ahead of print) |
| Smokers with chronic myeloid leukemia are at higher risk of disease progression and premature death (Lauseker M et al. Cancer, February 2017) (epub ahead of print) |
A review of the challenge in measuring and standardizing BCR-ABL1 (Yu S et al. Clin Chem Lab Med, Februar 2017) (epub ahead of print) |
|
Targeted therapies: Remembrance of things past - discontinuation of second-generation TKI therapy for CML |
The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukemia (Demyanets S et al. Br J Hematol, February 2017) (epub ahead of print) |
|
Pleural effusion in Dasatinib-treated patients with chronic myeloid leukemia in chronic phase: Identification and management |
The chronic myeloid leukemia stem cell: Stemming the tide of persistence (Holyoake T. et al. Blood, February 2017) |
| Increased peroxisome proliferator-activated receptor-gamma activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells (Wang J et al. Haematologica, February 2017) (epub ahead of print) |
|
| January 2017 | |
| Characterization of patients with chronic myeloid leukemia unresponsive to tyrosine kinase inhibitors who underwent hemoatopoietic stem cell transplantation (Carvalho FR et al. Int J Hematol Stem Cell Res, January 2017) |
Reduced CD62L expression on T cells and increased CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia (Sopper S et al. J Clin Oncol, January 2017) |
| Current approach to the treatment of chronic myeloid leukemia (Pasic I et al. Leuk Res, January 2017) |
CML patients with deep molecular responses to TKI have restored immune effects, decreased PD-1 and immune suppressor |
| Long-term follow-up of the French Stop Imatinib (STIM1) Study in patients with chronic myeloid leukemia (Etienne G. et al. J Clin Oncol, January 2017) |
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: Results in 1494 patients with chronic myeloid leukemia treated with imatinib |
| Current approach in the treatment of chronic myeloid leukemia (Pasic I et al. Leuk Res, January 2017) (epub ahead of print) |
Modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukemia (Banjar H et al. PLoS One, January 2017) |
| Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib (Ailawadhi S. et al. Ther Adv Hematol, January 2017) |
The hypothesis of the human iNKT/innate CD8(+) T-cells axis applied to Cancer: Evidence for a defiency in chronic myeloid leukemia (Jacomet F. et al. Front Immunol, January 2017) |
| Early BCR-ABL1 transcript decline after 1 month of tyrosine kinase inhibitor therapy as an indicator for treatment response in chronic myeloid leukemia (El Missiry M et al. PLoS One, January 2017) |
|
| Induction of p53 suppresses chronic myeloid leukemia (Peterson LF et al. Leuk Lymphoma, January 2017) (epub ahead of print) |
|
|
Epression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML |
|
